Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
11/26/11	$1.720	+1.18%	3,93,645
10/26/10	$1.700	+1.19%	9,491
09/26/09	$1.680	0.00%	29,603
08/26/08	$1.680	+1.20%	31,191
04/26/04	$1.660	-2.35%	63,178

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.720USD

Average target price

26.00USD

Spread / Average Target

+1,411.63%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 01:30:00 12/09/2026 am IST			5-day change	1st Jan Change
1.720 ^USD	+1.18%		+3.61%	-5.49%

11/09	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI

Market Cap	82.41L 71.01L 67.24L 60.94L 1.14Cr 79Cr 1.15Cr 7.99Cr 3.07Cr 40Cr 3.1Cr 3.03Cr 126.58Cr	P/E 2027 *	-1.64x	P/E 2028 *	-1.98x
Enterprise Value	82.41L 71.01L 67.24L 60.94L 1.14Cr 79Cr 1.15Cr 7.99Cr 3.07Cr 40Cr 3.1Cr 3.03Cr 126.58Cr	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	97.32%	Yield 2027 *	-	Yield 2028 *	-

11/09	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI
18/08	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop	CI
04/08	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
23/07	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI
22/07	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt	CI
22/07	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026	CI
07/04	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
26/03	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
16/03	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
16/03	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
12/03	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
07/03	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE

12/23/12	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
27/21/27	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
01/21/01	Alzamend Neuro : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

Alzamend Neuro, Inc. Share Price

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation : Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news : Alzamend Neuro, Inc.

Analysts' recommendations : Alzamend Neuro, Inc.

Press Releases : Alzamend Neuro, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

20/08	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC	PR
18/08	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain	PR
23/07	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
07/04	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
26/03	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR

1 day	+1.18%
1 week	+3.61%
Current month	+7.50%
1 month	+17.01%
3 months	+50.22%
6 months	-21.10%
Current year	-5.49%

1 week	1.58	1.76
1 month	1.41	1.76
Current year	0.84	2.54
1 year	0.84	2.68
3 years	0.84	360.31
5 years	0.84	4,819.5
10 years	0.84	45,292.48

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	20/11/2018
David Katzoff DFI	Director of Finance/CFO	64	05/08/2022
Henry Nisser LAW	General Counsel	57	01/05/2019

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	26/02/2016
William Horne CHM	Chairman	57	01/06/2021
Stephan Jackman BRD	Director/Board Member	50	01/09/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
26/08/26	Todd Ault	Sell	Founder	-2,000	0.0417%
26/08/26	HYPERSCALE DATA, INC.	Other	Company	0	0%	-
31/07/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.1565%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	+1.18%	+3.61%	-28.33%	-99.44%	82.41L
LONZA GROUP AG	-0.71%	-6.35%	-4.87%	+9.03%	4.55TCr
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+340.68%	+519.93%	4.37TCr
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+37.28%	+21.57%	4.31TCr
BEONE MEDICINES AG	+1.38%	-3.28%	+3.23%	+65.60%	3.94TCr
CELLTRION, INC.	-1.44%	-5.26%	+8.78%	+36.85%	3.19TCr
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	1.73TCr
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+18.07%	+110.32%	1.64TCr
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.47%	+30.49%	1.42TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+74.20%	+39.37%	1.33TCr
Average	+0.56%	-2.86%	+51.06%	+81.52%	2.65TCr
Weighted average by Cap.	+0.41%	-3.67%	+73.16%	+123.56%

	2027 *	2028 *
Net sales	-	-
Net income	-1.08Cr -93.05L -88.11L -79.86L -1.5Cr -103.18Cr -1.51Cr -10Cr -4.02Cr -52Cr -4.06Cr -3.97Cr -165.87Cr	-1.08Cr -93.05L -88.11L -79.86L -1.5Cr -103.18Cr -1.51Cr -10Cr -4.02Cr -52Cr -4.06Cr -3.97Cr -165.87Cr
Net Debt	-	-

Markets		Quality
Nasdaq	ALZN	Delayed
CBOE	ALZN	Real-time